ABSTRACT
Since the first description of endoluminal treatment for peripheral vascular disease by Dotter and Judkins in 1964,1
there has been a substantial increase in the number of patients treated using percutaneous transluminal angioplasty (PTA). Percutaneous transluminal angioplasty in its various forms has been used as an alternative to reconstructive surgery in patients with critical limb ischaemia and, because it is minimally invasive, the threshold for treatment of claudicants has been reduced.
